tirzepatide news november 2025 on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial Boston, USA. 16th Nov, 2025.

As awareness regarding the health impacts of obesity and diabetes increases and funding continues to flow, the market for GLP-1 receptor agonists is poised for substantial growth in the coming years

Why weight loss was not the driver Here is the finding that makes the study especially interesting

Results were presented at the 2025 EASD meeting and published in The New England Journal of Medicine

VEGF stands for vascular endothelial growth factor

How Semaglutide Dosing Is Structured Semaglutide belongs to a class of medications known as GLP-1 receptor agonists, which work by slowing digestion and reducing appetite signals in the brain